Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intra-Cellular Ther (NQ: ITCI )

92.55 +1.26 (+1.38%)
Streaming Delayed Price Updated: 12:13 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Intra-Cellular Ther

< Previous 1 2 3 4 5 Next >
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%
Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk reduction and favorable safety profile. 
Via Benzinga
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews
Via Benzinga
Earnings Preview For Intra-Cellular Therapies
Via Benzinga
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings)
Via Benzinga
Expert Ratings For Intra-Cellular Therapies
Via Benzinga
This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Via Benzinga
Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains'
Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
Via Benzinga
Where Intra-Cellular Therapies Stands With Analysts
Via Benzinga
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%). 
Via Benzinga
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Patterson Companies, Silk Road Medical, Micron, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Analyst Ratings For Intra-Cellular Therapies
Via Benzinga
The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
Via Benzinga
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
Intra-Cellular Therapies reports positive topline results for Study 502 on lumateperone 42 mg as adjunctive therapy for major depressive disorder. FDA application expected in H2 2024. 
Via Benzinga
Exposures Product Safety
Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win
The company hopes to expand its antipsychotic drug to depression treatment. 
Via Investor's Business Daily
The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio
While it’s comforting to pick the ideas of the masses, these overlooked stocks may offer superior upside potential for the daring. 
Via InvestorPlace
ITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024
ITCI stock results show that Intra-Cellular Therapies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
3 Biotech Stocks With Skyrocketing Potential: April 2024
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time. 
Via InvestorPlace
Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
The Nasdaq and S&P 500 tumbled below their 50-day lines. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
How Is The Market Feeling About Intra-Cellular Therapies?
Via Benzinga
Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study
Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular's Study 501, show significant symptom relief as adjunctive therapy to antidepressants. 
Via Benzinga
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results
Intra-Cellular Therapies is trying to position its antipsychotic in depression treatment. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.